Product Description
Mechanisms of Action: CD3 Inhibitor,PSMA Inhibitor
Novel Mechanism: No
Modality: Bispecific Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Prostate Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
TCD17896 | P2 |
Recruiting |
Prostate Cancer |
2027-09-29 |
49% |